Manufacturers: Eli lilly and co
Insulin lispro is a modified form of fast-acting insulin used to control hyperglycemia in diabetes mellitus.
Insulin lispro is a modified form of fast-acting insulin used to control hyperglycemia in diabetes mellitus.
Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.
本品尤其适用于下列情况： 1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率； 2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
3 associated conditions
